Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Pu H71
2. Pu-h71
1. Pu-h71
2. 873436-91-0
3. Pu-h 71
4. Pu H71
5. Zelavespib
6. Puh-71
7. Pu-h-71
8. 8-((6-iodobenzo[d][1,3]dioxol-5-yl)thio)-9-(3-(isopropylamino)propyl)-9h-purin-6-amine
9. Chembl200102
10. Cas#873436-91-0
11. 06ivk87m04
12. 6-amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-n-(1-methylethyl)-9h-purine-9-propanamine
13. Cas# 873436-91-0
14. 8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9-(3-(isopropylamino)propyl)-9h-purin-6-amine
15. 8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-9-[3-(isopropylamino)propyl]-9h-purin-6-amine
16. 8-[(6-iodo-1,3-benzodioxol-5-yl)sulfanyl]-9-[3-(propan-2-ylamino)propyl]purin-6-amine
17. H71
18. Unii-06ivk87m04
19. 2fwz
20. Nsc 750424
21. Zelavespib [inn]
22. Puh71
23. Schembl1857579
24. Pu-h71, D6
25. Dtxsid20236288
26. Ex-a315
27. Hms3653n04
28. Bcp03616
29. Nsc 750424-d6
30. Bdbm50180302
31. Nsc752199
32. S8039
33. Zinc13679213
34. Akos024457431
35. Ccg-269784
36. Cs-0546
37. Db12638
38. Nsc-752199
39. Sb17115
40. Ncgc00371072-06
41. Ac-33112
42. Bs-17694
43. Da-41005
44. Hy-11038
45. Bcp0726000178
46. Ft-0700388
47. Sw220214-1
48. J-690375
49. Brd-k36529613-001-01-8
50. Q27236209
51. 8-(6-iodo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(3-isopropylamino-propyl)adenine
52. 1-{2-[2-(2-fluoroethyl)-2h-tetrazol-5-yl]ethyl}-3-{5-[3-fluoro-4-(methylsulfonyl)phenyl]-4-methyl-1,3-thiazol-2-yl}urea
53. 8-(6-iodo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(3-isopropyl-aminopropyl-d6)adenine (pu-h71-d6)
54. 8-[(6-iodo-1,3-benzodioxol-5-yl)sulfanyl]-9-{3-[(1-methylethyl)amino]propyl}-9h-purin-6-amine
| Molecular Weight | 512.4 g/mol |
|---|---|
| Molecular Formula | C18H21IN6O2S |
| XLogP3 | 3.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 7 |
| Exact Mass | 512.04914 g/mol |
| Monoisotopic Mass | 512.04914 g/mol |
| Topological Polar Surface Area | 125 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 521 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
ABOUT THIS PAGE
58
PharmaCompass offers a list of SUPVGFZUWFMATN-UHFFFAOYSA-N API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right SUPVGFZUWFMATN-UHFFFAOYSA-N manufacturer or SUPVGFZUWFMATN-UHFFFAOYSA-N supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred SUPVGFZUWFMATN-UHFFFAOYSA-N manufacturer or SUPVGFZUWFMATN-UHFFFAOYSA-N supplier.
PharmaCompass also assists you with knowing the SUPVGFZUWFMATN-UHFFFAOYSA-N API Price utilized in the formulation of products. SUPVGFZUWFMATN-UHFFFAOYSA-N API Price is not always fixed or binding as the SUPVGFZUWFMATN-UHFFFAOYSA-N Price is obtained through a variety of data sources. The SUPVGFZUWFMATN-UHFFFAOYSA-N Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A 06IVK87M04 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 06IVK87M04, including repackagers and relabelers. The FDA regulates 06IVK87M04 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 06IVK87M04 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A 06IVK87M04 supplier is an individual or a company that provides 06IVK87M04 active pharmaceutical ingredient (API) or 06IVK87M04 finished formulations upon request. The 06IVK87M04 suppliers may include 06IVK87M04 API manufacturers, exporters, distributors and traders.
06IVK87M04 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 06IVK87M04 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 06IVK87M04 GMP manufacturer or 06IVK87M04 GMP API supplier for your needs.
A 06IVK87M04 CoA (Certificate of Analysis) is a formal document that attests to 06IVK87M04's compliance with 06IVK87M04 specifications and serves as a tool for batch-level quality control.
06IVK87M04 CoA mostly includes findings from lab analyses of a specific batch. For each 06IVK87M04 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
06IVK87M04 may be tested according to a variety of international standards, such as European Pharmacopoeia (06IVK87M04 EP), 06IVK87M04 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (06IVK87M04 USP).
